Flexion Therapeutics, Inc.
FLXN
FLXN was delisted on the 18th of November, 2021.
135 hedge funds and large institutions have $517M invested in Flexion Therapeutics, Inc. in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 42 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
8% more funds holding
Funds holding: 125 → 135 (+10)
7% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 42
13% less capital invested
Capital invested by funds: $591M → $517M (-$74.1M)
48% less call options, than puts
Call options by funds: $1.49M | Put options by funds: $2.87M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$47.1M |
| 2 |
BlackRock
New York
|
+$8.47M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$7.22M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$5.9M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.24M |
| 2 |
D.E. Shaw & Co
New York
|
-$5.72M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3.13M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.05M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$1.61M |
FLXN Hedge Fund Activity: Q3 2020 in Review
135 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Flexion Therapeutics, Inc. (FLXN) for Q3 2020, worth a combined $517M — down 13% from $591M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new FLXN positions and 10 closed out — a net gain of 10 holders — while 45 added to existing stakes and 42 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $47.1M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $6.24M sold.
- 135 institutional investors held Flexion Therapeutics, Inc. (FLXN) as of Q3 2020, up from 125 in Q2 2020.
- Funds reported $517M of Flexion Therapeutics, Inc. stock for Q3 2020, down 13% quarter-over-quarter.
- 20 funds opened new Flexion Therapeutics, Inc. positions in Q3 2020 and 10 closed out, a net change of +10 holders.
- The largest Flexion Therapeutics, Inc. buyer in Q3 2020 was Versant Venture Management, an estimated $47.1M added.
- The largest Flexion Therapeutics, Inc. seller in Q3 2020 was Balyasny Asset Management, an estimated $6.24M sold.
Based on aggregated 13F filings for Q3 2020.